Sphere Medical Holding plc Sphere Medical launches Proxima 4 (7731R)
2016年12月14日 - 4:00PM
RNSを含む英国規制内ニュース (英語)
TIDMSPHR
RNS Number : 7731R
Sphere Medical Holding plc
14 December 2016
14 December 2016
Sphere Medical Holding plc
("Sphere", "Sphere Medical" or the "Company")
Sphere Medical launches next generation analyser, Proxima 4
Sphere Medical Holding plc (AIM: SPHR.L), an innovative
point-of-care monitoring and diagnostic devices company, announces
the launch today of Proxima 4 in Europe. The launch of the next
generation product Proxima 4 follows the successful European launch
of Proxima 3 in September 2014.
Proxima 4, which gained CE Mark approval in September 2016, is
the new iteration of Sphere's already marketed innovative
patient-connected device used for measuring blood gases,
electrolytes and metabolites. It incorporates a number of
significant enhancements over the previously available product,
Proxima 3, including expansion of the panel of analytes and a
number of important usability improvements.
The expanded panel of analytes enables Proxima to be used with
additional groups of patients, including those requiring glycaemic
control and those undergoing cardiac surgery. Developments with
Proxima 4 also extend its use to include paediatric patients
weighing greater than 15 kilograms. As a result of these changes,
the target population of potential patients is estimated to
increase four fold to almost 50% of patients in intensive care
units.
Proxima 4 will be marketed directly by Sphere's own sales force
in the UK, Germany, The Netherlands and Belgium and Sphere plans to
market Proxima 4 through distributors in other countries. Burke
& Burke, appointed in July 2016 to market Proxima in Italy,
will now commence marketing Proxima 4. Sphere Medical is aiming to
put in place more distributorships in other European markets over
the coming months.
Wolfgang Rencken, the Company's Chief Executive Officer,
commented: "The European launch of Proxima 4, one of our strategic
objectives for 2016, is an important milestone for the Company on
the route to making the Company commercially successful. We look
forward to updating the market during 2017 on progress with the
marketing of Proxima 4, and on progress with further updates and
enhancements to the system."
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014.
- Ends -
For further information, please contact:
Sphere Medical Holding Tel: +44 (0)1223 875
plc 222
Dr Wolfgang Rencken, Chief
Executive Officer
Richard Wright, Chief
Financial Officer
Panmure Gordon Tel: +44 (0) 20 7886
2500
Freddy Crossley (Corporate
Finance)
Duncan Monteith (Corporate
Finance)
Tom Salvesen (Corporate
Broking)
Consilium Strategic Tel: +44 (0) 20 3709
Communications 5700
Mary-Jane Elliott spheremedical@consilium-comms.com
Ivar Milligan
Hendrik Thys
Notes for Editors
About Sphere Medical (AIM: SPHR.L)
Sphere Medical is an innovative point-of-care medical device
company. Its Proxima platform measures blood gases, electrolytes
and metabolites at the patient's bedside and aims to improve
patient care and reduce health system costs. The device is
currently sold directly to the critical care market via Sphere
Medical's sales force in the UK, Germany, The Netherlands and
Belgium and will be sold via a distributor in Italy. For further
information, please visit www.spheremedical.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
PRLAKNDPDBDBFBD
(END) Dow Jones Newswires
December 14, 2016 02:00 ET (07:00 GMT)
Sphere Medical (LSE:SPHR)
過去 株価チャート
から 5 2024 まで 6 2024
Sphere Medical (LSE:SPHR)
過去 株価チャート
から 6 2023 まで 6 2024